Recent research on various biomarkers for major depressive disorder (MDD) provide an opportunity to develop biosensors that can overcome the challenges faced by conventional diagnostic tools, MUNASET researchers say.
2D-BioPAD and MUNASET at Graphene Week 2025: Showcasing Graphene-Based Biomedical Innovation
Emergence of graphene-based biosensors for improved treatment response prediction in major depressive disorder: a perspective.
Enabling EU-funded project collaboration for brain health R&I
RIA PULSE: 4 HORIZON EUROPE PROJECTS IN ACTION
Joint Biomed Workshop during Graphene Week 2024 strengthens collaboration between 2D-BioPAD and MUNASET projects
Partners from the MUNASET project met to report their progress and set the objectives for upcoming work.
Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers.